{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+First&page=8",
    "query": {
      "intervention": "Placebo First",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 3253,
    "total_pages": 326,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+First&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+First&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T12:12:13.000Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04403399",
      "title": "Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Varenicline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2017-06-29",
      "completion_date": "2019-06-26",
      "has_results": true,
      "last_update_posted_date": "2021-01-27",
      "last_synced_at": "2026-10-18T12:12:13.000Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04403399"
    },
    {
      "nct_id": "NCT01231347",
      "title": "QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adenocarcinoma of the Pancreas",
        "Advanced Solid Tumors",
        "Cancer",
        "Cancer of Pancreas",
        "Cancer of the Pancreas",
        "Metastases",
        "Metastatic Cancer",
        "Metastatic Pancreatic Cancer",
        "Pancreas Cancer",
        "Pancreatic Cancer",
        "Bone Metastases",
        "Endocrine Cancer",
        "Oncology",
        "Oncology Patients",
        "Solid Tumors",
        "Advanced Malignancy"
      ],
      "interventions": [
        {
          "name": "AMG 479",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NantCell, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2011-04-07",
      "completion_date": "2012-12-12",
      "has_results": true,
      "last_update_posted_date": "2024-07-16",
      "last_synced_at": "2026-10-18T12:12:13.000Z",
      "location_count": 24,
      "location_summary": "Fullerton, California • La Jolla, California • Los Angeles, California + 18 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01231347"
    },
    {
      "nct_id": "NCT07167758",
      "title": "A Study Evaluating TRIV-509 in Atopic Dermatitis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "TRIV-509",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Triveni Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 95,
      "start_date": "2025-08-26",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-10-18T12:12:13.000Z",
      "location_count": 9,
      "location_summary": "Fountain Valley, California • San Diego, California • Miami, Florida + 6 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "South Bend",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07167758"
    },
    {
      "nct_id": "NCT03161964",
      "title": "Propranolol in Treating Hypoglycemia Unawareness",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Propranolol 80 Mg Oral Capsule, Extended Release",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anu Sharma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "21 Years to 59 Years"
      },
      "enrollment_count": 2,
      "start_date": "2017-10-19",
      "completion_date": "2019-12-19",
      "has_results": true,
      "last_update_posted_date": "2020-08-24",
      "last_synced_at": "2026-10-18T12:12:13.000Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03161964"
    },
    {
      "nct_id": "NCT01593605",
      "title": "Resveratrol-Leucine Metabolite Synergy in Pre-diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Impaired Glucose Tolerance"
      ],
      "interventions": [
        {
          "name": "Resveratrol",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "resveratrol /HMB",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2012-02",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2013-09-20",
      "last_synced_at": "2026-10-18T12:12:13.000Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01593605"
    },
    {
      "nct_id": "NCT01072669",
      "title": "Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ischemia"
      ],
      "interventions": [
        {
          "name": "ambrisentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Soumya Chatterjee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2010-02",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2013-05-03",
      "last_synced_at": "2026-10-18T12:12:13.000Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01072669"
    },
    {
      "nct_id": "NCT01844986",
      "title": "Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Newly Diagnosed",
        "Advanced Ovarian Cancer",
        "FIGO Stage III-IV",
        "BRCA Mutation",
        "Complete Response",
        "Partial Response",
        "First Line Platinum Chemotherapy"
      ],
      "interventions": [
        {
          "name": "Olaparib 300mg tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 450,
      "start_date": "2013-08-26",
      "completion_date": "2028-08-29",
      "has_results": true,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-10-18T12:12:13.000Z",
      "location_count": 81,
      "location_summary": "Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 63 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01844986"
    },
    {
      "nct_id": "NCT06252220",
      "title": "First in Human Study in Subjects With Obesity, But Otherwise Healthy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "DA-1726",
          "type": "DRUG"
        },
        {
          "name": "Placebo to DA-1726",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NeuroBo Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 139,
      "start_date": "2024-03-25",
      "completion_date": "2026-11-09",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-10-18T12:12:13.000Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06252220"
    },
    {
      "nct_id": "NCT00319488",
      "title": "Childhood Asthma Research and Education (CARE) Network Trial - Acute Intervention Management Strategies (AIMS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Asthma",
        "Lung Diseases"
      ],
      "interventions": [
        {
          "name": "Inhaled Corticosteroid (Budesonide)",
          "type": "DRUG"
        },
        {
          "name": "Leukotriene Receptor Antagonist (Montelukast Sodium)",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Albuterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "59 Months",
        "sex": "ALL",
        "summary": "12 Months to 59 Months"
      },
      "enrollment_count": 238,
      "start_date": "2004-02",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2016-07-29",
      "last_synced_at": "2026-10-18T12:12:13.000Z",
      "location_count": 6,
      "location_summary": "Tucson, Arizona • La Jolla, California • Denver, Colorado + 3 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00319488"
    },
    {
      "nct_id": "NCT02152605",
      "title": "A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "UMEC/VI",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 498,
      "start_date": "2014-09-01",
      "completion_date": "2015-03-05",
      "has_results": true,
      "last_update_posted_date": "2017-11-09",
      "last_synced_at": "2026-10-18T12:12:13.000Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Upland, California • Clearwater, Florida + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        },
        {
          "city": "Anderson",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02152605"
    }
  ]
}